Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera

Next Previous
Search
Trial Profile

A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rusfertide (Primary)
  • Indications Polycythaemia vera
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms REVIVE
  • Sponsors Protagonist Therapeutics

    • Most Recent Events

    • 25 Nov 2024 According to a Takeda media release, final result data from this phase 2 REVIVE study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2024, in San Diego, California.
    • 05 Nov 2024 According to a Protagonist Therapeutics media release, final data form this trial will be presented at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in San Diego from December 7-10, 2024.
    • 26 Mar 2024 According to a Protagonist Therapeutics media release, the REVIVE Phase 2 trial and other completed studies along with phase 3 pivotal trial will comprise the clinical data package planned for NDA filing in fourth quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top